195 related articles for article (PubMed ID: 30720920)
21. T1a Versus T1b Differentiated Thyroid Cancers: Do We Need to Make the Distinction?
Anderson KL; Youngwirth LM; Scheri RP; Stang MT; Roman SA; Sosa JA
Thyroid; 2016 Aug; 26(8):1046-52. PubMed ID: 27266722
[TBL] [Abstract][Full Text] [Related]
22. The effects of the Union for International Cancer Control/American Joint Committee on Cancer Tumour, Node, Metastasis system version 8 on staging of differentiated thyroid cancer: a comparison to version 7.
Verburg FA; Mäder U; Luster M; Reiners C
Clin Endocrinol (Oxf); 2018 Jun; 88(6):950-956. PubMed ID: 29573277
[TBL] [Abstract][Full Text] [Related]
23. Eighth edition of tumor-node-metastasis staging system improve survival predictability for papillary, but not follicular thyroid carcinoma: A multicenter cohort study.
Kim M; Kim HI; Jeon MJ; Kim HK; Kim EH; Yi HS; Kim ES; Kim H; Kim BH; Kim TY; Kim SW; Kang HC; Kim WB; Chung JH; Shong YK; Kim TH; Kim WG
Oral Oncol; 2018 Dec; 87():97-103. PubMed ID: 30527251
[TBL] [Abstract][Full Text] [Related]
24. Restaging of differentiated thyroid carcinoma by the sixth edition AJCC/UICC TNM staging system: stage migration and predictability.
Lang B; Lo CY; Chan WF; Lam KY; Wan KY
Ann Surg Oncol; 2007 May; 14(5):1551-9. PubMed ID: 17318278
[TBL] [Abstract][Full Text] [Related]
25. Modification of the eight-edition tumor-node-metastasis staging system with N1b for papillary thyroid carcinoma: A multi-institutional cohort study.
Kim M; Kim HK; Kim HI; Kim EH; Jeon MJ; Yi HS; Kim ES; Kim H; Kim TH; Kim BH; Kim TY; Kang HC; Kim WB; Chung JH; Shong YK; Kim SW; Kim WG
Oral Oncol; 2018 Nov; 86():48-52. PubMed ID: 30409319
[TBL] [Abstract][Full Text] [Related]
26. Comparison between the seventh and eighth edition of the AJCC/UICC staging system for nasopharyngeal cancer integrated with pretreatment plasma Epstein-Barr virus DNA level in a non-Chinese population: secondary analysis from a prospective randomized trial.
Kitpanit S; Jittapiromsak N; Sriyook A; Prayongrat A; Kannarunimit D; Chakkabat C; Lertbutsayanukul C
Jpn J Clin Oncol; 2019 Dec; 49(12):1100-1113. PubMed ID: 31334768
[TBL] [Abstract][Full Text] [Related]
27. Refining the tumor-node-metastasis staging system for individualized treatment of differentiated thyroid carcinoma.
Kim YN; Kim M; Ahn HS; Kim K; Park SY; Kim HI; Jeon MJ; Kim WG; Kim SW; Kim WB; Chung JH; Shong YK; Kim TY; Kim TH
Oral Oncol; 2019 Feb; 89():8-13. PubMed ID: 30732964
[TBL] [Abstract][Full Text] [Related]
28. Validation of the eighth edition of the AJCC staging system for patients with pancreatic adenocarcinoma initially receiving chemoradiotherapy and proposal of modifications.
Zhu X; Chen D; Cao Y; Zhao X; Ju X; Shen Y; Cao F; Qing S; Fang F; Jia Z; Zhang H
Cancer Biol Med; 2020 May; 17(2):492-500. PubMed ID: 32587784
[No Abstract] [Full Text] [Related]
29. Stage migration with the new American Joint Committee on Cancer (AJCC) staging system (8th edition) for differentiated thyroid cancer.
Shaha AR; Migliacci JC; Nixon IJ; Wang LY; Wong RJ; Morris LGT; Patel SG; Shah JP; Tuttle RM; Ganly I
Surgery; 2019 Jan; 165(1):6-11. PubMed ID: 30415873
[TBL] [Abstract][Full Text] [Related]
30. Changes in Stage Distribution and Disease-Specific Survival in Differentiated Thyroid Cancer with Transition to American Joint Committee on Cancer 8th Edition: A Systematic Review and Meta-Analysis.
Lechner MG; Bernardo AC; Lampe A; Praw SS; Tam SH; Angell TE
Oncologist; 2021 Feb; 26(2):e251-e260. PubMed ID: 32864832
[TBL] [Abstract][Full Text] [Related]
31. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP
J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506
[TBL] [Abstract][Full Text] [Related]
32. Differentiated thyroid cancer: A retrospective evaluation of the impact of changes to disease management guidelines on patients in South East Scotland.
Williamson AG; Wilmot V; Ntala C; Gibb FW; Conn B; Nixon IJ
Surgeon; 2019 Apr; 17(2):73-79. PubMed ID: 29884507
[TBL] [Abstract][Full Text] [Related]
33. Validation Study of the AJCC Cancer Staging Manual, Eighth Edition, Staging System for Eyelid and Periocular Squamous Cell Carcinoma.
Xu S; Sagiv O; Rubin ML; Sa HS; Tetzlaff MT; Nagarajan P; Ning J; Esmaeli B
JAMA Ophthalmol; 2019 May; 137(5):537-542. PubMed ID: 30869769
[TBL] [Abstract][Full Text] [Related]
34. A Relook at the T Stage of Differentiated Thyroid Carcinoma with a Focus on Gross Extrathyroidal Extension.
Song E; Lee YM; Oh HS; Jeon MJ; Song DE; Kim TY; Kim WB; Shong YK; Sung TY; Kim WG
Thyroid; 2019 Feb; 29(2):202-208. PubMed ID: 30358515
[TBL] [Abstract][Full Text] [Related]
35. Validation of the QTNM staging system for cancer-specific survival in patients with differentiated thyroid cancer.
Mankarios D; Baade P; Youl P; Mortimer RH; Onitilo AA; Russell A; Doi SA
Endocrine; 2014 Jun; 46(2):300-8. PubMed ID: 24174176
[TBL] [Abstract][Full Text] [Related]
36. Analysis of risk factors and prognosis in differentiated thyroid cancer with focus on minimal extrathyroidal extension.
Weber M; Binse I; Oebbecke K; Brandenburg T; Herrmann K; Theurer S; Weber F; Ehrlich AK; Schmid KW; Führer-Sakel D; Vardarli I; Fendler WP; Gilman E; Görges R
BMC Endocr Disord; 2021 Aug; 21(1):161. PubMed ID: 34376175
[TBL] [Abstract][Full Text] [Related]
37. A critical analysis of the American Joint Committee on Cancer (AJCC) staging system for differentiated thyroid carcinoma in young patients on the basis of the Surveillance, Epidemiology, and End Results (SEER) registry.
Tran Cao HS; Johnston LE; Chang DC; Bouvet M
Surgery; 2012 Aug; 152(2):145-51. PubMed ID: 22503316
[TBL] [Abstract][Full Text] [Related]
38. Interobserver Variability in the Histopathologic Assessment of Extrathyroidal Extension of Well Differentiated Thyroid Carcinoma Supports the New American Joint Committee on Cancer Eighth Edition Criteria for Tumor Staging.
Turk AT; Asa SL; Baloch ZW; Faquin WC; Fellegara G; Ghossein RA; Giordano TJ; LiVolsi VA; Lloyd R; Mete O; Rosai J; Suster S; Thompson LDR; Wenig BM
Thyroid; 2019 May; 29(5):619-624. PubMed ID: 30913992
[No Abstract] [Full Text] [Related]
39. Optimal cut-off age in the TNM Staging system of differentiated thyroid cancer: is 55 years better than 45 years?
Kim M; Kim YN; Kim WG; Park S; Kwon H; Jeon MJ; Ahn HS; Jung SH; Kim SW; Kim WB; Chung JH; Shong YK; Kim TH; Kim TY
Clin Endocrinol (Oxf); 2017 Mar; 86(3):438-443. PubMed ID: 27731521
[TBL] [Abstract][Full Text] [Related]
40. Impact of the updated TNM staging criteria on prediction of persistent disease in a differentiated thyroid carcinoma cohort.
Nava CF; Zanella AB; Scheffel RS; Maia AL; Dora JM
Arch Endocrinol Metab; 2019 Feb; 63(1):5-11. PubMed ID: 30864625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
